NLV-III Investment Opportunity
Epstein Suite indexes the text; the original document lives at its official source. We don't host the original file — view it on the official release to read it in full.
View the original on the official releaseDocument text
Text is machine OCR and may contain errors. Confirm against the original source above.
NLV-III Investment Opportunity
The objective of NLV-III is to invest in a portfolio of healthcare technology companies that offer
attractive risk-adjusted returns. The companies that comprise the portfolio will be selected and
managed by a team of highly experienced senior partners who have developed and proven
their investment process over many years and multiple funds. The investment strategy for
NLYV-II] is similar to the strategies pursued in prior funds, in that it will have a core focus on
biopharmaceutical investments with a balance of investments across other healthcare
technology sectors. Given the strength and stability of the team, the consistency and the depth
of the track record, and the positive market forces and investment conditions that are expected
to be in place during the life of the Fund, the Fund Managers believe NLV-III offers investors an
opportunity for attractive returns.
10 CONTROL NUMBER 257 - CONFIDENTIAL
HOUSE_OVERSIGHT_024021
Have a question about what this document contains?
Ask the documents